Case Reports
10 December 2024
Vol. 17 No. 2 (2025)
Stevens-Johnson syndrome/toxic epidermal necrolysis induced by lamotrigine in a patient with a cerebral cavernous malformation: a case report
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
516
Views
360
Downloads
6
HTML
Authors
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious cutaneous reactions characterized by epidermal and mucocutaneous detachment, most often drug-induced. SJS and TEN are considered the opposite extremes of the same spectrum of disease, where the percentage of skin involvement is <10% in SJS and >30% in TEN; the in-between range is called an SJS/TEN overlap. We present the case of a 64-year-old patient who was treated with lamotrigine, an anti-epileptic drug, and developed SJS/TEN. After being hospitalized and recovering for three days due to the worsening of the clinical presentation, he was transferred to a burn center. Making an early diagnosis and identifying the appropriate drug is crucial for setting the correct treatment and reducing mortality. Advanced supportive care is required.
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Espinosa-Aguilar E-J, Piña-Ballantyne S-A, Espinosa-Aguilar K-L, et al. Steven-Johnson Syndrome Induced by Lamotrigine and Valproic Acid in a Pediatric Patient: A Case Report. Cureus 2023;15:e41267. DOI: https://doi.org/10.7759/cureus.41267
2. Wang X, Xiong J, Xu W-H, et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure 2015;25:52-61. DOI: https://doi.org/10.1016/j.seizure.2014.12.001
3. Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev 2022;3:CD013130. DOI: https://doi.org/10.1002/14651858.CD013130.pub2
4. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-43. DOI: https://doi.org/10.1056/NEJMoa1013297
5. Bui VL, Alvarez-Arango S, Stevenson JM. Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated? Pharmacogenet Genomics 2024;34:16-9. DOI: https://doi.org/10.1097/FPC.0000000000000510
6. Mushiroda T, Takahashi Y, Onuma T, et al. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. JAMA Neurol 2018;75:842-9. DOI: https://doi.org/10.1001/jamaneurol.2018.0278
7. Aimo C, Mariotti EB, Corrà A, et al. Stevens-Johnson syndrome induced by Vaxvetria (AZD1222) COVID-19 vaccine. J Eur Acad Dermatol Venereol 2022;36:e417-9. DOI: https://doi.org/10.1111/jdv.17988
8. Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol 2023;64:e1-10. DOI: https://doi.org/10.1111/ajd.13958
9. Curtis KK, Dillan MM, Sharma TR, Piktel J. COVID-19 Infection Increases the Development of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Cohort Analysis. J Am Acad Dermatol 2024;90:1300-2. DOI: https://doi.org/10.1016/j.jaad.2024.02.029
10. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006;155:722-8. DOI: https://doi.org/10.1111/j.1365-2133.2006.07398.x
11. Caproni M, Antiga E, Parodi A, et al. Elevated circulating CD40 ligand in patients with
erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:1006-7. DOI: https://doi.org/10.1111/j.1365-2133.2006.07211.x
12. Marzano AV, Frezzolini A, Caproni M, et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007;20:557-66. DOI: https://doi.org/10.1177/039463200702000313
13. Cheng L. Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Front Pharmacol 2021;12:588063. DOI: https://doi.org/10.3389/fphar.2021.588063
14. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272-6. DOI: https://doi.org/10.1038/sj.jid.5700068
15. Hsieh M-H, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Front Med 2021;8[Accessed 19 Feb 2024]. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2021.636924. DOI: https://doi.org/10.3389/fmed.2021.636924
16. Chang H-C, Wang T-J, Lin M-H, Chen T-J. A Review of the Systemic Treatment of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis. Biomedicines 2022;10:2105. DOI: https://doi.org/10.3390/biomedicines10092105
17. Haoxiang X, Xu Y, Baoxi W. Lamotrigine-associated with toxic epidermal necrolysis: a case report and Chinese literature review. Int J Dermatol 2014;53:e231-2. DOI: https://doi.org/10.1111/j.1365-4632.2012.05800.x
How to Cite
Stevens-Johnson syndrome/toxic epidermal necrolysis induced by lamotrigine in a patient with a cerebral cavernous malformation: a case report. (2024). Dermatology Reports, 17(2). https://doi.org/10.4081/dr.2024.10007
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
